Proposals for Next Classification Schema of Myeloid Neoplasms
Endowed Chair in Biochemistry and Molecular Biotechnology I
School of Public Health and Health Sciences
Health Informatics And Implementation Science
Dr. Ionete is a clinical neuroimmunologist and educator with special interests including clinical trials in multiple sclerosis and other autoimmune neurological diseases, and neurological complications of HIV infections. She chairs the Department of Neurology's education committee.
Johnnie Ray Cox Term Chair in Biomedical Research
Dr. Henninger is a vascular neurologist with research interest in the neurobiology of axonal injury associated with traumatic brain injury and its contribution to functional outcome.
Immediate opening! Two postdoctoral positions are available immediately to study cellular andmolecular mechanisms resulting in immunosuppression after alcohol use. Thefocus of this research is the role of monocytes and dendritic cells indecreased antigen-specific T cell activation after alcohol use.Intracellular signalling mechanisms resulting in decreased NF-kBactivation and inflammatory cytokine induction after acute alcoholconsumption are being investigated. Please contact Dr. Szabo for details.
Richard M. Haidack Professor in Medicine
Research in Dr. Koupenova's lab focuses on the contribution of platelets to the immune response during viral infection and the consequent implications of that response to cardiovascular disease. For additional information about projects or joining the lab, contact Dr. Koupenova @ milka.koupenova@umassmed.edu
Idanis Berrios Morales, MD, is a board-certified neurologist and educator with clinical subspecialty training in neuroimmunology and multiple sclerosis. Her research interest is shared decision making in patients with multiple sclerosis.
There is a current project opening for using deep learning to train and ultimately perform automatic segmentation for multiple brain structures of interest in Multiple Sclerosis. Helpful background would include some proficiency in shell and Python. Please email me if interested.
Dr. Hemond is a board-certified neurologist with clinical subspecialty training in neuroimmunology and multiple sclerosis. His research focuses on the development and validation of MRI-based biomarkers to improve (1) early identification and (2) pathophysiological understanding of the neurodegenerative processes underlying MS.
Dr. John Meyers Professor in Primary Care Medicine
Population and Quantitative Health Sciences
Biochemistry and Molecular Biotechnology
Healthcare Delivery and Population Sciences at UMass Chan - Baystate
Preventing Osteoarthritis After an ACL Injury
Preventing Osteoarthritis After an ACL Injury Playing the Long Game: Consensus for Preventing OA
Preventing Osteoarthritis After an ACL Injury Playing the Long Game: Consensus for Preventing OA Characteristics of Accelerated Hand Osteoarthritis
Joseph D. Early Chair in Biomedical Research
Prevention Strategies for Second Primary Malignancies After CAR-T Therapy
The Darkest Side of AML: The TP53 Mutation
Clonal Hematopoiesis in Clinical Practice: Real-World Insights
Unpacking CHIP: Recent Updates, Remaining Questions
Dr Patel on the Impact of Donor-Engrafted Clonal Hematopoiesis on Outcomes With Auto-/Allo-HSCT
Effects of donor-engrafted clonal hematopoiesis in stem cell transplantation
High-Risk Myelodysplastic Syndrome Findings in the SELECT-MDS-1 Study
Stem Cell Transplantation: How Clonal Hematopoiesis Shapes Patient Outcomes
Olutasidenib as a Breakthrough for R/R mIDH1 AML Patients
The Impact of Mutations in Clonal Hematopoiesis
TP53 in MDS & AML Prognostication & Treatment Strategies
Exploring the Biological Basis of TP53-Aberrant MDS & AML
Improving Outcomes in Blast Phase Chronic Myeloid Leukemia
ASH Clinical News - Practical Solutions Amid Cuts to Federally Funded Research
OncLive with Dr. Patel and Dr. Gerber: p53 Immunohistochemistry
Early Identification of TP53-Mutant MDS and AML Using p53 Immunostaining
Point-of-Care p53 IHC Unveils TP53-Mutant MDS/AML
IHC Enables Rapid Identification of TP53-Mutant MDS/AML
ASH Clinical News: p53 Immunohistochemistry for TP53-Mutant MDS/AML
p53 Immunostain in TP53-Mutant MDS and AML